GMAB - Rasio utang marang kapitalisasi buku Genmab A/S

Strict FDA oversight and patent protection for bispecific antibodies create significant barriers to entry for competitors. Analyzing the monitoring of the company's debt-to-equity ratio on GURU.Markets, we note that 0.83 shows the level of this metric. A stable staff of R&D specialists and the impeccable reputation of Genmab A/S (GMAB) in global oncology guarantee leadership in the field of precision cancer therapy.

GMAB Genmab A/S: Rasio utang marang kapitalisasi buku ing interval 04.07.2022 - 27.10.2026

Ringkesan rincian data analitis Genmab AS (GMAB)

- rega lan prakiraan konsensus rega:

Rega saham Genmab A/S|GMAB - Target konsensus

- data kapitalisasi pasar:

Nilai pasar Genmab Corp|GMAB - Total Nilai Perusahaan

- data kapitalisasi buku:

Aset Bersih saben Siji Saham Genmab|GMAB - Nilai Buku Perusahaan|Rasio Nilai Pasar marang Nilai Buku genmab.com|GMAB - Aset Perusahaan

- data utang lan likuiditas:

Total Utang marang Modal Genmab A/S|GMAB - Tanggungan utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Genmab US|GMAB - Utang kumulatif perusahaan|Utang marang nilai buku Genmab Corp

Analisis kabeh metrik perusahaan:GMAB, Genmab A/S

This metric compares total liabilities to the book value of equity, allowing for a real-time assessment of debt load dynamics and asset devaluation risks. The stability of this capital structure risk indicator on the balance sheet confirms the financial resilience of Genmab A/S, which correlates with the flawless organization of high-tech logistics during the transportation of monoclonal antibodies to medical centers.

Pesaing Genmab A/S (GMAB)